Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Tysabri withdrawal calls entire class into question

Nature Medicine volume 11, page 359 (2005)Cite this article

Similar drugs may all pose a risk of infections, experts say.

The future of a promising treatment for multiple sclerosis (MS) is in question after two patients takinag the drug were diagnosed with a rare neurological disorder.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Boston

    Emily Singer

Authors
  1. Emily Singer
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Natalizumab

Israeli researchers eye simple test for multiple sclerosis

Fast track to MS drug

Related external links

Tysabri

Progressive multifocal leukoencephalopathy

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singer, E. Tysabri withdrawal calls entire class into question. Nat Med 11, 359 (2005). https://doi.org/10.1038/nm0405-359a

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nm0405-359a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing